Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials

BACKGROUND: Upadacitinib (UPA) is an oral Janus kinase (JAK) inhibitor approved for the treatment of rheumatoid arthritis (RA). JAK inhibitors have been associated with an increased risk of herpes zoster (HZ) in patients with RA. OBJECTIVES: To evaluate the incidence and risk factors for HZ in UPA-t...

Descripción completa

Detalles Bibliográficos
Autores principales: Winthrop, Kevin L, Nash, Peter, Yamaoka, Kunihiro, Mysler, Eduardo, Khan, Nasser, Camp, Heidi S, Song, Yanna, Suboticki, Jessica L, Curtis, Jeffrey R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761994/
https://www.ncbi.nlm.nih.gov/pubmed/34615638
http://dx.doi.org/10.1136/annrheumdis-2021-220822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761994/
https://www.ncbi.nlm.nih.gov/pubmed/34615638
http://dx.doi.org/10.1136/annrheumdis-2021-220822

Ejemplares similares